Literature DB >> 11943708

Role of beta-catenin/T-cell factor-regulated genes in ovarian endometrioid adenocarcinomas.

Yali Zhai1, Rong Wu, Donald R Schwartz, Danielle Darrah, Heather Reed, Frank T Kolligs, Marvin T Nieman, Eric R Fearon, Kathleen R Cho.   

Abstract

In various cancers, inactivating mutations in the adenomatous polyposis coli or Axin tumor suppressor proteins or activating mutations in beta-catenin's amino-terminal domain elevate beta-catenin levels, resulting in marked effects on T-cell factor (TCF)-regulated transcription. Several candidate beta-catenin/TCF-regulated genes in cancer have been proposed. Expression of a few of these genes has been studied in primary human cancers, but most studies have focused on colon cancers and not on other cancer types that harbor mutational defects in adenomatous polyposis coli, AXIN, or beta-catenin. Mutations leading to beta-catenin deregulation are found in nearly half of ovarian endometrioid adenocarcinomas (OEAs). We report here on the expression of 6 candidate beta-catenin/TCF-regulated genes in a panel of 44 primary OEAs, more than a third of which carry demonstrable defects in beta-catenin regulation. Using quantitative assays of gene expression, we found significantly elevated expression of the MMP-7, CCND1 (Cyclin D1), CX43 (Connexin 43), PPAR-delta, and ITF2 genes in OEAs with deregulated beta-catenin. This correlation was not observed for c-myc, another putative beta-catenin/TCF-regulated gene. Immunohistochemical studies confirmed that overexpression of cyclin D1 and MMP-7 was highly associated with nuclear accumulation of beta-catenin and mutational defects of the Wnt/beta-catenin/TCF-signaling pathway. Our findings indicate cyclin D1, MMP-7, connexin 43, PPAR-delta, and ITF-2, likely play important roles in the pathogenesis of those OEAs that manifest defects in beta-catenin regulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943708      PMCID: PMC1867221          DOI: 10.1016/s0002-9440(10)62550-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  60 in total

1.  Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1.

Authors:  J Roose; G Huls; M van Beest; P Moerer; K van der Horn; R Goldschmeding; T Logtenberg; H Clevers
Journal:  Science       Date:  1999-09-17       Impact factor: 47.728

2.  Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer.

Authors:  K Hovanes; T W Li; J E Munguia; T Truong; T Milovanovic; J Lawrence Marsh; R F Holcombe; M L Waterman
Journal:  Nat Genet       Date:  2001-05       Impact factor: 38.330

3.  Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.

Authors:  H Takayasu; H Horie; E Hiyama; T Matsunaga; Y Hayashi; Y Watanabe; S Suita; M Kaneko; F Sasaki; K Hashizume; T Ozaki; K Furuuchi; M Tada; N Ohnuma; A Nakagawara
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

4.  Detection and analysis of beta-catenin mutations in prostate cancer.

Authors:  D R Chesire; C M Ewing; J Sauvageot; G S Bova; W B Isaacs
Journal:  Prostate       Date:  2000-12-01       Impact factor: 4.104

5.  beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.

Authors:  C Gamallo; J Palacios; G Moreno; J Calvo de Mora; A Suárez; A Armas
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

6.  Differential interactions of Id proteins with basic-helix-loop-helix transcription factors.

Authors:  K Langlands; X Yin; G Anand; E V Prochownik
Journal:  J Biol Chem       Date:  1997-08-08       Impact factor: 5.157

7.  beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours.

Authors:  K Wright; P Wilson; S Morland; I Campbell; M Walsh; T Hurst; B Ward; M Cummings; G Chenevix-Trench
Journal:  Int J Cancer       Date:  1999-08-27       Impact factor: 7.396

8.  Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway.

Authors:  L Mirabelli-Primdahl; R Gryfe; H Kim; A Millar; C Luceri; D Dale; E Holowaty; B Bapat; S Gallinger; M Redston
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

9.  beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer.

Authors:  T Brabletz; A Jung; S Dag; F Hlubek; T Kirchner
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

10.  Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas.

Authors:  S Sagae; K Kobayashi; Y Nishioka; M Sugimura; S Ishioka; M Nagata; K Terasawa; T Tokino; R Kudo
Journal:  Jpn J Cancer Res       Date:  1999-05
View more
  37 in total

1.  Expression of the Wnt antagonist DKK3 is frequently suppressed in sporadic epithelial ovarian cancer.

Authors:  An You; Emmanouil Fokas; Lin-Fang Wang; Haitao He; Beate Kleb; Dieter Niederacher; Rita Engenhart-Cabillic; Han-Xiang An
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-09       Impact factor: 4.553

2.  MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.

Authors:  Y Zhai; A Iura; S Yeasmin; A B Wiese; R Wu; Y Feng; E R Fearon; K R Cho
Journal:  Oncogene       Date:  2011-04-18       Impact factor: 9.867

3.  S-Adenosylmethionine regulates connexins sub-types expressed by hepatocytes.

Authors:  Sachie Yamaji; Anna Droggiti; Shelly C Lu; Maria L Martinez-Chantar; Anne Warner; Marta Varela-Rey
Journal:  Eur J Cell Biol       Date:  2010-11-18       Impact factor: 4.492

4.  Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis.

Authors:  Yu-Jun Li; Zhi-Min Wei; Yun-Xiao Meng; Xiang-Rui Ji
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

5.  HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression.

Authors:  Y Li; J H Bavarva; Z Wang; J Guo; C Qian; S N Thibodeau; E A Golemis; W Liu
Journal:  Oncogene       Date:  2011-02-14       Impact factor: 9.867

6.  Norcantharidin impairs medulloblastoma growth by inhibition of Wnt/β-catenin signaling.

Authors:  Flora Cimmino; Maria Nunzia Scoppettuolo; Marianeve Carotenuto; Pasqualino De Antonellis; Valeria Di Dato; Gennaro De Vita; Massimo Zollo
Journal:  J Neurooncol       Date:  2011-07-07       Impact factor: 4.130

Review 7.  Gap Junctions and Wnt Signaling in the Mammary Gland: a Cross-Talk?

Authors:  Sabreen F Fostok; Mirvat El-Sibai; Marwan El-Sabban; Rabih S Talhouk
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

Review 8.  Wnt signaling in ovarian tumorigenesis.

Authors:  T A Gatcliffe; B J Monk; K Planutis; R F Holcombe
Journal:  Int J Gynecol Cancer       Date:  2007-11-06       Impact factor: 3.437

9.  Targeted deletion of Kcne2 causes gastritis cystica profunda and gastric neoplasia.

Authors:  Torsten K Roepke; Kerry Purtell; Elizabeth C King; Krista M D La Perle; Daniel J Lerner; Geoffrey W Abbott
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

10.  Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer.

Authors:  Chenghai Zhao; Xianmin Bu; Ning Zhang; Wei Wang
Journal:  BMC Cancer       Date:  2009-07-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.